Tag: DCB
DCB vs plain balloon AV access angioplasty: More investigation is needed,...
At the recent Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (14–18 September, Lisbon, Portugal), Kate Steiner (East and North Herts NHS...
Renal Interventions’ top 10 stories of September 2024
September brought with it six-month trial outcomes, funding updates, and all-time lows, with Merit Medical presenting six-month results from the Wrapsody WAVE trial, Venova...
Long-term IN.PACT AV data show there is “definitely a place” for...
Matteo Tozzi (Varese, Italy) and Kate Steiner (Stevenage, UK) sat down with Vascular News at this year’s Charing Cross (CX) International Symposium (23–25 April,...
Renal Interventions’ top 10 stories of April 2024
April was a month of world-firsts, new collaborations, and useful data, with a team from Massachusetts General Hospital (Boston, USA) performing the world’s first...
“We know which DCB to use”—but many other questions remain in...
A first-time presentation of five-year data from the IN.PACT AV Access study evaluating the IN.PACT AV (Medtronic) drug-coated balloon (DCB) today led principal investigator...
Light-activated drug-coated balloon granted FDA approval for clinical study
Alucent Biomedical has announced that the Food and Drug Administration (FDA) granted an investigational device exemption (IDE) for a US clinical study of AlucentNVS,...
DCB superior to plain balloon for stent graft stenosis in Taiwanese...
Recent studies have evaluated drug-coated balloon (DCB) treatments’ ability to help maintain arteriovenous fistula (AVF) patency for haemodialysis patients “with mixed results”, according to...
Daniel Patel
American Society of Diagnostic and Interventional Nephrology (ASDIN) certification and accreditation chairman Daniel Patel is the medical director for interventional nephrology at the Volusia-Flagler...
PAVE-2, paclitaxel and sirolimus-coated balloons for AVF
Michael Robson and Narayan Karunanithy (King’s College London, London, UK) write to explore the range of options in drug-coated balloons (DCBs) for stenosis in...
Renal Interventions’ top 10 stories of February 2023
The 19th annual scientific meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN; 17–19 February, Orlando, USA) loomed large in February, with...
Experts react to “compelling” 36-month IN.PACT AV Access trial data
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Shahverdyan (Hamburg, Germany), Matteo Tozzi (Varese, Italy), Alexandros Mallios (Paris,...
Live from ASDIN: DCB or not DCB? “Compelling” evidence demands more...
The second day of the 2023 meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN; 17–19 February, Orlando, USA) played host to...
VentureMed to present new data on DCB treatment for PAD
VentureMed Group has announced new data presentations on the treatment of peripheral arterial disease (PAD) with drug-coated balloon (DCBs) in addition to 12-month AV...
History warns us against “optimistic exuberance” in drug-coated balloon trials
The importance of assessing clinical trial data in an objective, balanced way has been borne out by recent history in the vascular surgery space,...
EVA meeting harnesses global, multidisciplinary experts and analysis to guide the...
Lively discussion on unmet needs and building on quiet developments in vascular access from leading surgeons, interventional radiologists, nephrologists and interventional nephrologists formed the...
New sirolimus data provide encouragement despite “potentially disappointing” efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...
First time data release: View the full IN.PACT AV Access trial...
NOTE: This video is ONLY available to watch in selected countries and geographies
In a late-breaking Podium 1st presentation at the 2022 Charing Cross...
Plain balloon first and drug-eluting balloon second? The role of DCBs...
Kate Steiner (Stevenage, UK) discusses existing clinical evidence on drug-coated balloons (DCBs) in the treatment of arteriovenous access stenosis—and outlines areas where further data...
IN.PACT AV DCB “first and only” to show sustained and superior...
Medtronic has announced new randomised controlled data demonstrating the sustained and superior performance of the IN.PACT AV drug-coated balloon (DCB) compared to percutaneous transluminal...
IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...
Multidisciplinary UK panel agrees roadmap and optimal interventions for symptomatic AVF...
Multidisciplinary panel of UK experts agrees on roadmap and optimal stepwise application of interventions for symptomatic AVF stenoses in haemodialysis patients. Ounali Jaffer (London,...
Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF
Concept Medical has provided an update on the progress of the IMPRESSION (sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis access dysfunction)...
Balloon angioplasty in critical time window central to endovascular success for...
Tackling the main culprit, stenosis in the arteriovenous anastomosis and outflow veins, with balloon angioplasty before it is “too late” can boost maturation rates...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
New England Journal Of Medicine publishes “outstanding” six-month IN.PACT AV Access™...
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Lookstein (New York, USA; principal investigator) and Andrew Holden (Auckland,...
‘Indisputable evidence’ that DCB is the “gold standard” for treating vascular...
NOTE: This video is ONLY available to watch in selected countries and geographies
Tobias Steinke (Düsseldorf, Germany), Matteo Tozzi (Varese, Italy) and Robert Shahverdyan...
PAVE trial finds “no evidence of a benefit” from paclitaxel-coated balloons...
There is no evidence of a benefit from additional paclitaxel-coated balloon use compared to standard balloon angioplasty alone in the context of preserving arteriovenous...